The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Basic and Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://ncbi.nlm.nih.gov/pubmed/25398374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados